TABLE 1

Clinical summary of patients in this studya

Patient IDAge (yr)Clinical summarySputum cultureInpatient antibioticsOutpatient antibiotic(s)
19Severe lung disease on BPAP. Two hospitalizations, 1 mo apartMSSA, P. aeruginosaCefe, TobAzi, Tob (inhaled)
219Mild lung diseaseMSSA, AchromobacterP-T, Col (inhaled)Azi, Tob (inhaled)
312Mild lung diseaseMSSAOxa, Cefe, TobTob (inhaled)
414Mild lung disease. Mycobacterium abscessus was detected on cultureMSSA, mucoid P. aeruginosaP-T, TobTob (inhaled)
517Mild lung disease. Failed outpatient antibiotics (amoxicillin-clavulanic acid). Initial P. aeruginosa detected on culture. M. abscessus was detected on culture. Treated at home with intravenous antibiotics from day 6MSSA, P. aeruginosaP-T, TobNone
614Mild lung disease. Allergic bronchopulmonary aspergillosisMRSA, mucoid P. aeruginosaCeft, Tob, VanAzi, Azt (inhaled), Tob (inhaled)
717Severe lung disease on BPAP. CF-related diabetes. Mycobacterium avium was detected on culture, not treated. Required prolonged antibiotics for 19 days due to poor initial responseMSSA, mucoid P. aeruginosaAmi, Mero, CiproAzt, Tob (both inhaled)
817Moderate lung disease. CF-related diabetes. M. abscessus was detected on cultureRare P. aeruginosaNAAzi, Ami (inhaled)
922Mild lung diseaseFew MSSA, rare mucoid P. aeruginosaCefe, TobAzi, Tob (inhaled), Azt (inhaled)
1017Severe lung disease on BPAP. CF liver disease following liver transplantFew Achromobacter sp. organismsNAAzt, Col (both inhaled)
  • a Abbreviations: BPAP, bilevel positive airway pressure; Ami, amikacin; Azi, azithromycin; Azt, aztreonam; Cefe, cefepime; Ceft, ceftazidime; Cipro, ciprofloxacin; Col, colistin; Mero, meropenem; Oxa, oxacillin; P-T, piperacillin-tazobactam; Tob, tobramycin; Van, vancomycin; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; ID, identification. Lung disease severity was based on FEV1: mild, FEV1 ≥ 70%; moderate, FEV1 = 40% to 69%; severe, FEV1 < 40%.